Title:
PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF INFLAMMATORY RESPIRATORY DISEASE, WITH FUSION PROTEIN OF CELL PERMEABLE PEPTIDE AND CTCTLA4 PEPTIDE CONTAINED AS EFFECTIVE INGREDIENT THEREIN
Document Type and Number:
WIPO Patent Application WO/2018/182301
Kind Code:
A1
Abstract:
The present invention relates to a pharmaceutical composition comprising a fusion protein as an effective ingredient for prevention or treatment of an inflammatory respiratory disease, wherein the fusion protein has a cell permeable peptide fused with the ctCTLA4 peptide. In an administration manner via a respiratory route through which an effective therapeutic or prophylactic effect has not been conventionally achieved, the present invention has a remarkably outstanding permeability and efficiency to bronchial and pulmonary cells and remarkably improved activity of suppressing cytokine expression and airway inflammation, alleviating hypersensitive responses of the airway to allergens and Th2 inflammation, etc., compared to conventional therapeutic agents for inflammatory respiratory diseases, inter alia, allergic asthma. Therefore, the present invention can bring about a prompt, rapid, and efficient therapeutic or prophylactic effect.
Inventors:
CHOI JE-MIN (KR)
LIM SANGHO (KR)
LIM SANGHO (KR)
Application Number:
PCT/KR2018/003622
Publication Date:
October 04, 2018
Filing Date:
March 27, 2018
Export Citation:
Assignee:
IUCF HYU (KR)
International Classes:
A61K38/16; A61K9/00
Foreign References:
| KR20170022943A | 2017-03-02 | |||
| KR20080084937A | 2008-09-22 | |||
| US20140322183A1 | 2014-10-30 | |||
| KR20080066962A | 2008-07-17 |
Other References:
LIM, S. ET AL.: "dNP2 Is a Blood-brain Barrier-permeable Peptide Enabling ctCTLA-4 Protein Delivery to Ameliorate Experimental Autoimmune Encephalomyelitis", NATURE COMMUNICATIONS, vol. 6, 15 September 2015 (2015-09-15), pages 1 - 13, XP055368583
NIE, W. ET AL.: "Cytotoxic T-lymphocyte Associated Antigen 4 Polymorphisms and Asthma Risk: a Meta-analysis", PLOS ONE, vol. 7, no. 7, 26 July 2012 (2012-07-26), pages e42062, XP055559865
LIM, S. ET AL.: "dNP2-ctCTLA-4 Inhibits German Cockroach Extract-induced Allergic Airway Inflammation and Hyper-responsiveness via Inhibition of Th2 Responses", EXPERIMENTAL & MOLECULAR MEDICINE, vol. 49, no. 8, 4 August 2017 (2017-08-04), pages e362, XP055559867
"Remington's Pharmaceutical Sciences", MACK PUBLISHING COMPANY
See also references of EP 3603659A4
NIE, W. ET AL.: "Cytotoxic T-lymphocyte Associated Antigen 4 Polymorphisms and Asthma Risk: a Meta-analysis", PLOS ONE, vol. 7, no. 7, 26 July 2012 (2012-07-26), pages e42062, XP055559865
LIM, S. ET AL.: "dNP2-ctCTLA-4 Inhibits German Cockroach Extract-induced Allergic Airway Inflammation and Hyper-responsiveness via Inhibition of Th2 Responses", EXPERIMENTAL & MOLECULAR MEDICINE, vol. 49, no. 8, 4 August 2017 (2017-08-04), pages e362, XP055559867
"Remington's Pharmaceutical Sciences", MACK PUBLISHING COMPANY
See also references of EP 3603659A4
Attorney, Agent or Firm:
CHUNG HYUN PATENT & LAW FIRM (KR)
Download PDF: